BACKGROUND: Many coronary heart disease (CHD) events occur in individuals classified as intermediate risk by commonly used assessment tools. Over half the individuals presenting with a severe cardiac event, such as myocardial infarction (MI), have at most one risk factor as included in the widely used Framingham risk assessment. Individuals classified as intermediate risk, who are actually at high risk, may not receive guideline recommended treatments. A clinically useful method for accurately predicting 5-year CHD risk among intermediate risk patients remains an unmet medical need. OBJECTIVE: This study sought to develop a CHD Risk Assessment (CHDRA) model that improves 5-year risk stratification among intermediate risk individuals. METHODS: Assay panels for biomarkers associated with atherosclerosis biology (inflammation, angiogenesis, apoptosis, chemotaxis, etc.) were optimized for measuring baseline serum samples from 1084 initially CHD-free Marshfield Clinic Personalized Medicine Research Project (PMRP) individuals. A multivariable Cox regression model was fit using the most powerful risk predictors within the clinical and protein variables identified by repeated cross-validation. The resulting CHDRA algorithm was validated in a Multiple-Ethnic Study of Atherosclerosis (MESA) case-cohort sample. RESULTS: A CHDRA algorithm of age, sex, diabetes, and family history of MI, combined with serum levels of seven biomarkers (CTACK, Eotaxin, Fas Ligand, HGF, IL-16, MCP-3, and sFas) yielded a clinical net reclassification index of 42.7% (p < 0.001) for MESA patients with a recalibrated Framingham 5-year intermediate risk level. Across all patients, the model predicted acute coronary events (hazard ratio = 2.17, p < 0.001), and remained an independent predictor after Framingham risk factor adjustments. LIMITATIONS: These include the slightly different event definition with the MESA samples and inability to include PMRP fatal CHD events. CONCLUSIONS: A novel risk score of serum protein levels plus clinical risk factors, developed and validated in independent cohorts, demonstrated clinical utility for assessing the true risk of CHD events in intermediate risk patients. Improved accuracy in cardiovascular risk classification could lead to improved preventive care and fewer deaths.
BACKGROUND: Many coronary heart disease (CHD) events occur in individuals classified as intermediate risk by commonly used assessment tools. Over half the individuals presenting with a severe cardiac event, such as myocardial infarction (MI), have at most one risk factor as included in the widely used Framingham risk assessment. Individuals classified as intermediate risk, who are actually at high risk, may not receive guideline recommended treatments. A clinically useful method for accurately predicting 5-year CHD risk among intermediate risk patients remains an unmet medical need. OBJECTIVE: This study sought to develop a CHD Risk Assessment (CHDRA) model that improves 5-year risk stratification among intermediate risk individuals. METHODS: Assay panels for biomarkers associated with atherosclerosis biology (inflammation, angiogenesis, apoptosis, chemotaxis, etc.) were optimized for measuring baseline serum samples from 1084 initially CHD-free Marshfield Clinic Personalized Medicine Research Project (PMRP) individuals. A multivariable Cox regression model was fit using the most powerful risk predictors within the clinical and protein variables identified by repeated cross-validation. The resulting CHDRA algorithm was validated in a Multiple-Ethnic Study of Atherosclerosis (MESA) case-cohort sample. RESULTS: A CHDRA algorithm of age, sex, diabetes, and family history of MI, combined with serum levels of seven biomarkers (CTACK, Eotaxin, Fas Ligand, HGF, IL-16, MCP-3, and sFas) yielded a clinical net reclassification index of 42.7% (p < 0.001) for MESApatients with a recalibrated Framingham 5-year intermediate risk level. Across all patients, the model predicted acute coronary events (hazard ratio = 2.17, p < 0.001), and remained an independent predictor after Framingham risk factor adjustments. LIMITATIONS: These include the slightly different event definition with the MESA samples and inability to include PMRP fatal CHD events. CONCLUSIONS: A novel risk score of serum protein levels plus clinical risk factors, developed and validated in independent cohorts, demonstrated clinical utility for assessing the true risk of CHD events in intermediate risk patients. Improved accuracy in cardiovascular risk classification could lead to improved preventive care and fewer deaths.
Authors: Teresa Mateo; Yafa Naim Abu Nabah; May Abu Taha; Manuel Mata; Miguel Cerdá-Nicolás; Amanda E I Proudfoot; Rolf A K Stahl; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo; Peter J Jose; Maria-Jesus Sanz Journal: J Immunol Date: 2006-05-01 Impact factor: 5.422
Authors: Leticia Castillo; Anand Rohatgi; Colby R Ayers; Andrew W Owens; Sandeep R Das; Amit Khera; Darren K McGuire; James A de Lemos Journal: J Interferon Cytokine Res Date: 2010-05 Impact factor: 2.607
Authors: Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: Raymond Tabibiazar; Roger A Wagner; Euan A Ashley; Jennifer Y King; Rossella Ferrara; Joshua M Spin; David A Sanan; Balasubramanian Narasimhan; Robert Tibshirani; Philip S Tsao; Bradley Efron; Thomas Quertermous Journal: Physiol Genomics Date: 2005-05-03 Impact factor: 3.107
Authors: Sophie Hill; Janet Spink; Dominique Cadilhac; Adrian Edwards; Caroline Kaufman; Sophie Rogers; Rebecca Ryan; Andrew Tonkin Journal: BMC Public Health Date: 2010-03-04 Impact factor: 3.295
Authors: Umesh N Khot; Monica B Khot; Christopher T Bajzer; Shelly K Sapp; E Magnus Ohman; Sorin J Brener; Stephen G Ellis; A Michael Lincoff; Eric J Topol Journal: JAMA Date: 2003-08-20 Impact factor: 56.272
Authors: Cecilia Berardi; Christine L Wassel; Paul A Decker; Nicholas B Larson; Phillip S Kirsch; Mariza de Andrade; Michael Y Tsai; James S Pankow; Michele M Sale; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Mary M McDermott; Michael H Criqui; Michael A Allison; Suzette J Bielinski Journal: Angiology Date: 2016-07-20 Impact factor: 3.619
Authors: Nancy Swords Jenny; Nels C Olson; Matthew A Allison; Dena E Rifkin; Lori B Daniels; Ian H de Boer; Christina L Wassel; Russell P Tracy Journal: Glob Heart Date: 2016-09
Authors: Zhan Ye; Daniel A Vasco; Tonia C Carter; Murray H Brilliant; Steven J Schrodi; Sanjay K Shukla Journal: Front Genet Date: 2014-05-09 Impact factor: 4.599
Authors: Christian Luck; Vincent G DeMarco; Abuzar Mahmood; Madhavi P Gavini; Lakshmi Pulakat Journal: Oxid Med Cell Longev Date: 2017-03-20 Impact factor: 6.543
Authors: Matthew D Solomon; Ahalya Tirupsur; Evangelos Hytopoulos; Michael Beggs; Douglas S Harrington; Cynthia French; Thomas Quertermous Journal: Clin Cardiol Date: 2013-08-08 Impact factor: 2.882
Authors: Mario Luca Morieri; Hetal S Shah; Jennifer Sjaarda; Petra A Lenzini; Hannah Campbell; Alison A Motsinger-Reif; He Gao; Laura Lovato; Sabrina Prudente; Assunta Pandolfi; Marcus G Pezzolesi; Ronald J Sigal; Guillaume Paré; Santica M Marcovina; Daniel M Rotroff; Elisabetta Patorno; Luana Mercuri; Vincenzo Trischitta; Emily Y Chew; Peter Kraft; John B Buse; Michael J Wagner; Sharon Cresci; Hertzel C Gerstein; Henry N Ginsberg; Josyf C Mychaleckyj; Alessandro Doria Journal: Diabetes Date: 2020-01-23 Impact factor: 9.461
Authors: Parveen K Garg; Petra Buzkova; Christina L Wassell; Matthew Allison; Michael Criqui; Nicholas B Larson; Suzette J Bielinski Journal: Angiology Date: 2020-03-23 Impact factor: 3.619